The antibody-drug conjugate target landscape across a broad range of tumour types

The antibody-drug conjugate target landscape across a broad range of tumour types Annals of Oncology, mdx541, https://doi.org/10.1093/annonc/mdx541 K.L. Moek D.J.A. de Groot E.G.E. de Vries R.S.N. Fehrmann Background Antibody-drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics.…

Theranostics Using Antibodies and Antibody-Related Therapeutics

Theranostics Using Antibodies and Antibody-Related Therapeutics. J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S. doi: 10.2967/jnumed.116.186940. Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers and Elisabeth G.E. de Vries In theranostics, radiolabeled compounds are used to determine a treatment strategy…

Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and in vivo Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets

Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and in vivo Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets. Theranostics 2017; 7(2):482-492. doi:10.7150/thno.16816 Elmire Hartmans, Veronique Orian-Rousseau, Alexandra Matzke-Ogi, Arend Karrenbeld, Derk Jan A. de Groot, Steven de Jong, Gooitzen M. van Dam, Rudolf S.N. Fehrmann*, Wouter B. Nagengast* * Contributed equally…

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer paper is now accessible online at the Journal of the National Cancer Institute. JNCI J Natl Cancer Inst (2017) 109 (1): djw192 doi: 10.1093/jnci/djw192 Rico D. Bense, Christos Sotiriou, Martine J. Piccart-Gebhart, John B. A. G. Haanen, Marcel A. T. M.…

Identification of Novel Therapeutic Targets in Anaplastic Thyroid Carcinoma using Functional Genomic mRNA-Profiling: Paving the way for New Avenues?

Surgery. 2016, In press. Pascal K.C. Jonker, Gooitzen M. van Dam, Sjoukje F. Oosting, Schelto Kruijff, Rudolf S.N. Fehrmann. Background: Currently, anaplastic thyroid carcinoma (ATC) has a very poor prognosis and there is an unmet need for new therapeutic options. Therefore, this study aims to identify upregulated genes in ATC with known drug interactions that…

Genetic variants in RBFOX3 are associated with sleep latency

Eur J Hum Genet. 2016 May 4. Najaf Amin, Karla V Allebrandt, Ashley van der Spek, Bertram Müller-Myhsok, Karin Hek, Maris Teder-Laving, Caroline Hayward, Tõnu Esko, Josine G van Mill, Hamdi Mbarek, Nathaniel F Watson, Scott A Melville, Fabiola M Del Greco, Enda M Byrne, Edwin Oole, Ivana Kolcic, Ting-hsu Chen, Daniel S Evans, Josef…

Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types

Oncotarget. 2015 Jul 1. [Epub ahead of print] Laetitia E. Lamberts, Derk Jan A. de Groot, Rico D. Bense, Elisabeth G.E. de Vries, Rudolf S.N. Fehrmann The membrane bound glycoprotein mesothelin (MSLN) is a highly specific tumor marker, which is currently exploited as target for drugs. There are only limited data available on MSLN expression…